Distribution of gynecologic malignancies in an epidemiologic study from southeast of Turkey

Abstract

Abstract. Retrospective evaluation of 105 patients with gynecologic malignancy. One hundred and five patients with gynecologic malignancies diagnosed at Obstetrics and Gynecology Clinics of Medical School, Dicle University, Diyarbakir, between 2001 and 2005 were analyzed retrospectively. Gynecologic malignancies were classified. Distribution of 105 patients with gynecologic malignancies were; cervical cancer 19.04 % , endometrial cancer  21.90 %, uterine sarcoma  10.47%, primary ovarian cancer  40.95%, metastatic ovarian cancer 5.71%, carcinoma of the fallopian tubes 0.95%, choriocarcinoma  0.95%.  17 of 20 (85 %) patients with invasive cervical cancer were in stage≤IIa. Endometrioid cancer was the predominant (86.95%) histologic type in 23 patients with endometrial cancer. Leiomyosarcoma  was the most frequent (72.72%) histologic type in 11 patients with uterine sarcoma. 33 of 43 patients (76.74%) with ovarian cancer had epithelial type carcinoma. Six patients had metastatic ovarian cancer and  4 patients (66.66%)  in this group had Krukenberg tumors (signet-ring cells), 1 patient had primary tubal adenocarcinoma and 1 patient had choriocarcinoma. Ovarian cancer was the most frequent gynecologic malignancy in our study.

Key words: Gynecologic malignancy, epidemiology

Keywords

• -

References

1. 1. Hossfeld DK. Manual Of Clinical Oncology, 5th Ed., Springer- Verlag, UICC, 1992.
2. 2. Bilir N, Cakır B. Epidemiology of gynecologic cancers. In: Ayhan A et al. (eds). Basic Gynecology and Obstetrics (2nd ed). Ankara, Turkey: Gunes Medicine Bookstores, 2008, pp 1027.
3. 3. Globocan: Cancer incidence, Mortality, and Prevalence Worldwide, Version 1.0. IARC Cancer Base No.5 Lyon, IARCPress, 2001.
4. 4. Chı DS, Abu-Rustum NR, Plante M, Roy M. Cancer of the cervix. In: Rock JA, Jones III HW (eds). Te Linde’s Operative Gynecology (10th ed). Philadelphia: Lippincott Williams&Wilkins, 2008, pp 1227.
5. 5. Armstrong DK. Relapsed ovarian cancer. Challenges and management strategies for a chronic disease. Oncologist 2002; 7: 20-28.
6. 6. Berek JS, Hacker NF. Practical gynecologic oncology (2nd ed). Maryland &Wilkins 1994; 7: 243-283.
7. 7. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23- 47.
8. 8. Lurain JR. Uterine cancer. In Berek JS (eds). Novak’s Gynecology (13th ed). Philadelphia: Lippincott Williams&Wilkins, 2002, pp 1147.

9. 9. Ayhan A, Basaran A. Endometrial carcinoma. In: Ayhan A, et al. (eds). Basic Gynecology and Obstetrics (2nd ed). Ankara, Turkey: Gunes Medicine Bookstores, 2008, pp 1241.
10. 10. Creasman WT. Malignant tumors of the uterine corpus. In: Rock JA, Jones III HW (eds). Te Linde’s Operative Gynecology (9th ed). Philadelphia: Lippincott Williams&Wilkins, 2003, pp 1474.
11. 11. Ayhan A, Tuncer ZS, Tanir M, Yuce K. Uterine sarcoma: The Hacettepe Hospital experience of 88 patients. Eur J Gynecol Oncol 1997; 182: 146-148.
12. 12. Poveda A. Ovarian cancer. Is the news good enough?. Int J Gynecol Cancer 2005; 15: 298- 306.
13. 13. Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE. Carcinoma of fallopian tube: a clinicopathological study of 105 cases with observations on stating and prognostic factors. Gynecol Oncol 1999; 72: 367-379.
14. 14. Aziz S, Kuperstein G, Rosen B, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001; 80: 341-345.